The increase in price target by Mizuho suggests a positive outlook on the value of Neurocrine Biosciences, potentially leading to increased investor interest and a short-term positive impact on the stock price. However, the Neutral rating indicates that the analyst sees the stock as fairly valued at its current price, balancing the potential for both upside and downside.